Alm. Brand A/S
1.9.2025 09:29:45 CEST | Globenewswire | Press release
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S share buy-back program
Transactions during 25 August 2025 – 29 August 2025
On 5 March 2025, Alm. Brand A/S announced a share buy-back program of up to DKK 835.2 million, as described in company announcement no. 21/2025.
The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.
The following transactions were made under the share buy-back program during week number 35
| Number of shares bought | Average purchase price | Amount (DKK) | |
| Accumulated, last announcement | 23,675,000 | 16.36 | 387,330,750 |
| 25 August 2025 | 150,000 | 18.54 | 2,781,000 |
| 26 August 2025 | 150,000 | 18.59 | 2,788,500 |
| 27 August 2025 | 150,000 | 18.28 | 2,742,000 |
| 28 August 2025 | 170,000 | 17.91 | 3,044,700 |
| 29 August 2025 | 170,000 | 17.89 | 3,041,300 |
| Total, week number 35 | 790,000 | 18.22 | 14,397,500 |
| Accumulated under the program | 24,465,000 | 16.42 | 401,728,250 |
With the transactions stated above Alm. Brand A/S holds a total of 28,710,696 own shares corresponding to 1.98 % of the total number of outstanding shares.
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Head of Investor Relations & ESG
Mads Thinggaard
Mobile no. +45 2025 5469
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S24.10.2026 13:00:00 CEST | Press release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
ASYAD24.10.2026 12:47:36 CEST | Press release
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom